The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that SPRAVATO®▼ (esketamine) nasal spray has been granted reimbursement in Ireland for the treatment of adults living with treatment-resistant major depressive disorder (TRD), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI). People are considered to have TRD if they have not responded to at least two different treatments with antidepressants in the current moderate-to-severe depressive episode.1
Ireland has one of the highest rates of mental illness in Europe. It is estimated that approximately 150,000 people per year are living with severe depression. (Also known as Major Depressive Disorder or MDD) here.2,3 Major Depressive Disorder (MDD), the underlying disorder associated with Treatment Resistant Depression (TRD), is a severely debilitating psychiatric disorder. For these patients, the main goal of treatment is to relieve the symptoms of depression. This is while ultimately achieving remission, with few, if any, symptoms of depression remaining.4 However, about one third of people with MDD do not respond to currently available treatments.5
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
